[1] Riganta D. Clinical overview of vasculitic syndromes in the pediatric age [J]. Eur-Rev-Med-Pharmacol-Sci,2006,10(6):337-345. [2] Ozaltin F, Besbas N, Uckan D, et al. The role of apoptosis in childhood henoch-schonlein purpura[J]. Clinical rheumatology,2003,22(4/5):265-267. [3] Carlo-del VG, Rosa P, Maria A, et al. Cytokine pattern and endothelium damage markers in Henoch-Schonlein purpura.[J]. Immunopharmacology and Immunotoxicology, 2008, 30(3):623-629. [4] 胡亚美,江载芳.诸福棠实用儿科学(上册)[M].7版. 北京:人民卫生出版社,2005:688-690. [5] Prais D, Amir J, Nussinovitch M. Recurrent henoch-schonlein purpura in children [J]. J Clin Rheumatol, 2007,13(10):25-28. [6] Yang YH, Wang SJ, Chuang YH, et al. The level of IgA antibodies to human umbilical vein endothelial cells canbe enhancedby TNF-alpha treatment in children with Henoch-Schonlein purpura[J]. Clin Exp Immunol,2002,130:352-357. [7] Yu YH, Pan KL, Li Q, et al. Roles of serum and urinary interleukins 13Ralpha2 and other cytokines in pediatricHenoch-Schonlein purpura[J]. Zhongguo Dang Dai Er Ke Za Zhi,2009,11(1):37-40. [8] Duan B, Morel L. Role of B-1a cells in autoimmunity[J]. Autoimmun Rev,2006,5:403-408. [9] Yang YH, Huang YH, Lin YL, et al. Circulating IgA from acute stage of childhood Henoch-Schonlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway[J]. Clin Exp Immunol,2006,144:247-253. [10] Yildiz B, Kural N, Aydin BM, et al. Increased serum levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3 in Henoch-Schonlein purpura[J]. The Tohoku Journal of Experimental Medicine,2008,214(4):333-340. |